← Human Trials & Peer-Reviewed Studies
COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES
Plain-language guide to PMID 26574791 (2016): double-blind randomized controlled trial study of Liraglutide.
Key Facts
- PMID
- 26574791
- Journal
- Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
- Year
- 2016
- Study type
- Randomized Controlled Trial
- Authors
- Gilbert MP et al. (7 authors)
- DOI
- 10.4158/EP15758.OR
- Registered trial
- NCT00294723
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Liraglutide, published as a randomized controlled trial.
This subgroup analysis aimed to compare long-term effects of liraglutide and glimepiride on bone mineral density (BMD) in patients with type 2 diabetes.
Who Took Part
The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.
A 52-week, open-label extension followed, in which participants remained on randomized therapy.
A subgroup of participants underwent BMD measurement by dual-energy X-ray absorptiometry at baseline, 52, and 104 weeks.
How the Study Was Run
The design is described as randomized, double-blind, open-label and multicenter.
The participants were allocated by chance, so the Liraglutide group and the comparison group should start out alike.
As a double-blind Liraglutide study, the assignments were hidden from both participants and investigators until the end.
Nothing was hidden in this open-label Liraglutide study: the participants and staff both knew the treatment.
More than one site took part, so the participants came from several places.
The main outcome measure was change from baseline in total body BMD at 52 and 104 weeks, assessed by analysis of covariance.
What Was Measured
Topics PubMed links to this paper include Bone Density, Calcium, Diabetes Mellitus, Type 2, Fractures, Bone, Hypoglycemic Agents, Liraglutide and Sulfonylurea Compounds.
What This Means in Plain Language
The paper is a randomized, double-blind and open-label study of Liraglutide.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2016 (Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists), a journal based in United States.
More context: the Liraglutide compound page.
Our Notes on the Compound
Liraglutide: A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.